Emerging Lentiviral Vector Market Trend 2025-2034: Technological Advancements In Lentiviral Vector Production For Immuno-Oncology Therapies

How Is the Lentiviral Vector Market Projected to Grow, and What Is Its Market Size?
The lentiviral vector market will grow from $14.37 billion in 2024 to $16.62 billion in 2025, at a CAGR of 15.7%. This market is expanding due to the growing prevalence of genetic disorders, increasing demand for gene delivery systems, biotech and pharmaceutical investments, and regulatory approvals for related therapies.

The lentiviral vector market is expected to grow to $29.41 billion by 2029, fueled by the rise of personalized medicine, gene editing, and demand for rare disease therapies. Trends include expansion in CAR-T therapy, vaccine development, and innovations in production technologies.

What Are the Key Drivers Behind the Growth of the Lentiviral Vector Market?
The growing prevalence of chronic diseases is expected to drive the growth of the lentiviral vectors market. Chronic diseases are long-term conditions that typically progress slowly and may persist for years or a lifetime. The prevalence of chronic diseases is rising due to aging populations, unhealthy lifestyles, urbanization, and environmental factors. Lentiviral vectors provide efficient tools for developing vaccines and treatments for chronic diseases, improving patient outcomes, and addressing unmet medical needs. For example, in September 2024, the British Heart Foundation reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with these conditions contributing to 27% of all deaths in the UK, resulting in over 170,000 deaths annually. As a result, the increasing prevalence of chronic diseases is driving the growth of the lentiviral vectors market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14742&type=smp

Who Are the Major Industry Players Fueling Lentiviral Vector Market Expansion?
Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

How Is the Lentiviral Vector Market Evolving?
In the lentiviral vectors market, major companies are advancing the development of LV vector production platforms like LentiSure to improve the efficiency and robustness of lentivirus vector production for immuno-oncology treatments. For example, in May 2023, Yposkesi sk pharmteco, a French company, launched LentiSure, a platform aimed at optimizing lentiviral vector production. This platform is designed to meet the increasing demand for efficient and scalable viral-vector manufacturing in cell and gene therapies. It ensures consistent product quality, with typical titers of 10e7 IG/mL per bioreactor volume, thus enhancing productivity for cell therapy developers.

How Is the Segmentation of the Lentiviral Vector Market Defined?
The lentiviral vector market covered in this report is segmented -

1) By Product Type: Kits, Reagents And Consumables
2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications
3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes

Subsegments:
1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits
2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/lentiviral-vector-global-market-report

What Is the Leading Region in the Lentiviral Vector Market?
North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Lentiviral Vector Global Market Report?

- Market Size Analysis: Analyze the Lentiviral Vector Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Lentiviral Vector Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Lentiviral Vector Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Lentiviral Vector Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.